Abeona Therapeutics Inc. (0H7R.L)
USD 5.88
(-2.0%)
USD 5.88
(-2.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 4.4 Million USD | -24.8% |
| 2022 | 5.85 Million USD | -22.57% |
| 2021 | 7.56 Million USD | 429.41% |
| 2020 | 1.42 Million USD | -77.16% |
| 2019 | 6.25 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 16.13 Million USD | -10.76% |
| 2024 Q1 | 18.07 Million USD | 310.7% |
| 2023 Q3 | 4.04 Million USD | -7.63% |
| 2023 Q1 | 5.53 Million USD | -5.53% |
| 2023 FY | 4.4 Million USD | -24.8% |
| 2023 Q2 | 4.37 Million USD | -20.85% |
| 2023 Q4 | 4.4 Million USD | 8.88% |
| 2022 Q1 | 7.27 Million USD | -3.8% |
| 2022 FY | 5.85 Million USD | -22.57% |
| 2022 Q4 | 5.85 Million USD | -9.72% |
| 2022 Q3 | 6.48 Million USD | -3.76% |
| 2022 Q2 | 6.73 Million USD | -7.37% |
| 2021 FY | 7.56 Million USD | 429.41% |
| 2021 Q1 | 1.2 Million USD | -81.92% |
| 2021 Q3 | 4.44 Million USD | -5.93% |
| 2021 Q4 | 7.56 Million USD | 70.19% |
| 2021 Q2 | 4.72 Million USD | 290.57% |
| 2020 Q1 | 6.01 Million USD | -3.81% |
| 2020 FY | 1.42 Million USD | -77.16% |
| 2020 Q2 | 5.76 Million USD | -4.07% |
| 2020 Q3 | 5.51 Million USD | -4.35% |
| 2020 Q4 | 6.68 Million USD | 21.23% |
| 2019 Q4 | 6.25 Million USD | -3.56% |
| 2019 FY | 6.25 Million USD | 0.0% |
| 2019 Q3 | 6.48 Million USD | -3.37% |
| 2019 Q2 | 6.7 Million USD | -3.16% |
| 2019 Q1 | 6.92 Million USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | 81.938% |
| Dynavax Technologies Corporation | 252.41 Million USD | 98.256% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 86.739% |
| Perrigo Company plc | 3.63 Billion USD | 99.879% |
| Illumina, Inc. | 1.48 Billion USD | 99.704% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.986% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -340.2% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 99.945% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.966% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 97.467% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.837% |
| Unity Biotechnology, Inc. | 23.53 Million USD | 81.299% |
| Waters Corporation | 2.3 Billion USD | 99.809% |
| Biogen Inc. | 7.18 Billion USD | 99.939% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | 86.866% |
| Evolus, Inc. | 120.35 Million USD | 96.343% |
| Adicet Bio, Inc. | 17.7 Million USD | 75.134% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 88.128% |
| bluebird bio, Inc. | 224.41 Million USD | 98.038% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 99.122% |
| FibroGen, Inc. | 89.69 Million USD | 95.092% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.839% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -35.922% |
| Homology Medicines, Inc. | 43.17 Million USD | 89.805% |
| Geron Corporation | 35.05 Million USD | 87.441% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 99.812% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 98.865% |
| Myriad Genetics, Inc. | 130.9 Million USD | 96.637% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -370.299% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 95.45% |
| Zoetis Inc. | 6.56 Billion USD | 99.933% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 99.777% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 99.258% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 99.393% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 87.125% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 99.686% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 90.366% |
| Verastem, Inc. | 40.08 Million USD | 89.019% |
| Nektar Therapeutics | 112.62 Million USD | 96.091% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 97.528% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -43.201% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 99.611% |
| OPKO Health, Inc. | 222.03 Million USD | 98.017% |
| Exelixis, Inc. | 189.94 Million USD | 97.682% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 98.296% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | 96.616% |
| Imunon, Inc. | 1.13 Million USD | -286.38% |
| Blueprint Medicines Corporation | 610.96 Million USD | 99.279% |
| Insmed Incorporated | 1.19 Billion USD | 99.631% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.706% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 92.276% |
| TG Therapeutics, Inc. | 100.11 Million USD | 95.603% |
| Incyte Corporation | 29.16 Million USD | 84.905% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 99.014% |